Supernus Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, SUPN, Supernus Pharmaceuticals Inc, priceseries

Supernus Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
30.30
Close
30.08
High
30.46
Low
29.60
Previous Close
30.24
Daily Price Gain
-0.16
YTD High
33.30
YTD High Date
Feb 18, 2022
YTD Low
27.87
YTD Low Date
Mar 1, 2022
YTD Price Change
0.00
YTD Gain
0.00%
52 Week High
34.50
52 Week High Date
Nov 17, 2021
52 Week Low
23.15
52 Week Low Date
Aug 20, 2021
52 Week Price Change
4.57
52 Week Gain
17.91%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 18. 2017
33.65
Jun 12. 2017
38.02
16 Trading Days
12.98%
Link
LONG
Mar 2. 2018
39.65
Mar 14. 2018
42.19
8 Trading Days
6.40%
Link
LONG
May 10. 2018
49.90
May 21. 2018
53.31
7 Trading Days
6.84%
Link
LONG
Jan 4. 2019
34.34
Jan 24. 2019
36.09
13 Trading Days
5.08%
Link
LONG
Apr 23. 2020
18.85
Jun 1. 2020
24.05
26 Trading Days
27.61%
Link
LONG
Dec 18. 2020
21.88
Jan 21. 2021
28.38
21 Trading Days
29.73%
Link
LONG
Apr 1. 2021
26.72
Apr 28. 2021
31.28
18 Trading Days
17.06%
Link
Company Information
Stock Symbol
SUPN
Exchange
NasdaqGM
Company URL
http://www.supernus.com
Company Phone
301-838-2500
CEO
Jack A. Khattar
Headquarters
Maryland
Business Address
1550 E GUDE DR, ROCKVILLE, MD 20850
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001356576
About

Supernus Pharmaceuticals, Inc. develops and commercializes products for the treatment of central nervous system. It also develops multiple product candidates in psychiatry to address the large market opportunity in the treatment of attention deficit hyperactivity disorder, or ADHD, including ADHD patients with impulsive aggression. The company markets their products in the U.S. through their own focused sales force targeting specialty physicians and seek strategic collaborations with other pharmaceutical companies to license their products outside the U.S. Its neurology portfolio consists of Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended release topiramate). The company's psychiatry product candidates include SPN-810 (molindone hydrochloride), SPN-812 and SPN-809. Supernus Pharmaceuticals was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Description

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading